ABCZY:OTC-Abcam plc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 17.25

Change

+0.10 (+0.58)%

Market Cap

USD 3.71B

Volume

1.59K

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Company Website : http://www.abcam.com

Address : Discovery Drive, Cambridge, United Kingdom, CB2 0AX

Employees : 1,150

Fiscal Year End : June

Currency: USD

Country : USA

Technical Indicators

Beta : 0.66

52 Week High : 19.73

52 Week Low : 11.26

200 Day Moving Average : 16.52

50 Day Moving Average : 17.39

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

+1.59 (+2.46%)

 USD151.91B 25.08 2.66
CMXHF CSL Limited

N/A

 USD91.70B 45.27 25.24
CSLLY CSL Limited

-1.61 (-1.60%)

 USD90.73B 45.42 25.24
SBMFF Sino Biopharmaceutical Limited

+0.07 (+3.51%)

 USD23.67B 60.66 3.20
SBHMY Sino Biopharmaceutical Limited

N/A

 USD23.15B 63.08 3.20
UCBJY UCB SA

N/A

 USD22.93B 24.53 16.51
UCBJF UCB SA

N/A

 USD22.69B 24.72 16.51
GNMSF Genmab A/S

+8.56 (+2.50%)

 USD22.27B 59.66 6.37
PPTDF PeptiDream Inc

N/A

 USD5.53B 260.99 1.43
IDRSF Idorsia Ltd

-0.73 (-2.16%)

 USD4.89B 130.60 N/A

ETFs Containing ABCZY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.22% 40% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.22% 40% F 57% F
Trailing 12 Months  
Capital Gain -1.71% 51% F 64% D
Dividend Return 0.61% 33% F 11% F
Total Return -1.10% 50% F 62% D-
Trailing 5 Years  
Capital Gain 118.63% 80% B- 83% B
Dividend Return 6.91% 62% D- 35% F
Total Return 125.54% 81% B- 82% B-
Average Annual (5 Year Horizon)  
Capital Gain 17.89% 63% D 69% D+
Dividend Return 0.90% 57% F 28% F
Total Return 18.80% 65% D 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 23.71% 91% A- 73% C
Risk Adjusted Return 79.28% 98% A+ 96% A
Market Capitalization 3.71B 96% A 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 64.43 18% F 9% F
Price/Book Ratio 7.50 48% F 16% F
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA 38.32 12% F 7% F
Management Effectiveness  
Return on Equity 11.47% 86% B 76% C
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets 7.91% 95% A 92% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.66 57% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector